Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

NCT06412198 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT06412198
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06412198 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 28, 2024
Completion date
March 1, 2029
Enrollment
31 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

kras g12c mutations, metastatic colorectal cancer